Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy.

abstract：OBJECTIVES:Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the pharmacokinetics of ...

journal_title：HIV medicine

authors： Zorrilla CD,Wright R,Osiyemi OO,Yasin S,Baugh B,Brown K,Coate B,Verboven P,Mrus J,Falcon R,Kakuda TN

更新日期：2014-01-01 00:00:00

abstract：OBJECTIVE:The aim of the study was to describe Veterans Healthcare Administration (VHA) system-wide uptake of three HIV protease inhibitors: atazanavir, darunavir and tipranavir. METHODS:This retrospective cohort study evaluated VHA uptake of three target antiretrovirals and lopinavir/ritonavir in each complete 90-day...

journal_title：HIV medicine

authors： Belperio PS,Mole LA,Boothroyd DB,Backus LI

更新日期：2010-03-01 00:00:00

abstract：OBJECTIVES:The aim of the study was to systematically review current studies reporting on clinical outcomes in people living with HIV (PLHIV) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS:We conducted a systematic review using the Preferred Reporting Items for Systematic Reviews a...

journal_title：HIV medicine

authors： Cooper TJ,Woodward BL,Alom S,Harky A

更新日期：2020-10-01 00:00:00

abstract：OBJECTIVES:With the prolonged survival time of AIDS patients, complications of various systems and organs of HIV infection are increasingly prominent. These diseases have become the major factors influencing the quality of life and prognosis of HIV-infected persons, and multidisciplinary cooperation treatment is urgent...

journal_title：HIV medicine

authors： Lin L,Li TS

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Limited studies have suggested increased incidence rates and unusual clinical presentations of appendicitis among HIV-infected patients during the pre-highly active antiretroviral therapy (HAART) era. Data in the HAART era are sparse, and no study has evaluated potential HIV-related risk factors for the deve...

journal_title：HIV medicine

authors： Crum-Cianflone N,Weekes J,Bavaro M

更新日期：2008-07-01 00:00:00

abstract：OBJECTIVES:The aim of the study was to explore the awareness of rectal microbicides, the use of pre-exposure prophylaxis (PREP) and the willingness to participate in biomedical HIV prevention trials in a cohort of HIV-negative gay men. METHODS:In a community-based cohort study, HIV-negative homosexually active men in ...

journal_title：HIV medicine

authors： Poynten IM,Jin F,Prestage GP,Kaldor JM,Imrie J,Grulich AE

更新日期：2010-04-01 00:00:00

abstract：:A 25-year-old HIV-infected African albino woman developed an aggressive Merkel cell carcinoma on her face and at least 10 basal cell carcinomas, mainly on sun-exposed parts of her body. HIV infection, immune deficiency and sun exposure are known risk factors for the development of Merkel cell carcinoma. Chemotherapy a...

journal_title：HIV medicine

authors： Colebunders R,Bottieau E,Van den Brande J,Colpaert C,Van Marck E

更新日期：2004-11-01 00:00:00

abstract：:We describe the characteristics of HIV post-exposure prophylaxis (PEP) recipients and PEP indications at 56 Dean Street, a central London sexual health clinic. PEP was prescribed on 577 occasions. Most (97%) was given for unprotected anal intercourse. Over a fifth of exposures involved recreational drug use. Of the pa...

journal_title：HIV medicine

authors： Whitlock G,Nwokolo N,McOwan A

更新日期：2015-09-01 00:00:00

abstract：OBJECTIVES:Community HIV testing represents an opportunity for diagnosing HIV infection among individuals who may not have contact with health services, especially in hard-to-reach groups. The aim of this review was to assess the evidence for feasibility, acceptability and effectiveness of HIV testing strategies in com...

journal_title：HIV medicine

authors： Thornton AC,Delpech V,Kall MM,Nardone A

更新日期：2012-08-01 00:00:00

abstract：OBJECTIVES:Whether treatment-experienced HIV-1-infected patients with an acquired K103N mutation after failing nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens can be treated with rilpivirine is unknown. The aim of this pilot study was to evaluate the efficacy of rilpivirine/tenofovir/emtricitabine in HIV...

journal_title：HIV medicine

authors： Rokx C,Verbon A,Rijnders BJ

更新日期：2014-11-01 00:00:00

abstract：OBJECTIVES:The aim of the study was to compare the neuropsychiatric safety and tolerability of rilpivirine (TMC278) vs. efavirenz in a preplanned pooled analysis of data from the ECHO and THRIVE studies which compared the safety and efficacy of the two drugs in HIV-1 infected treatment naïve adults. METHODS:ECHO and T...

journal_title：HIV medicine

authors： Mills AM,Antinori A,Clotet B,Fourie J,Herrera G,Hicks C,Madruga JV,Vanveggel S,Stevens M,Boven K,ECHO and THRIVE study groups.

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Highly active antiretroviral therapy (HAART) has increased longevity. Currently, women comprise >50% of HIV-infected individuals worldwide. It is not known if there are differences between the sexes in the immunological and virological responses to HAART across the age strata. METHODS:Immunological reconsti...

journal_title：HIV medicine

authors： Patterson K,Napravnik S,Eron J,Keruly J,Moore R

更新日期：2007-09-01 00:00:00

abstract：OBJECTIVES:To compare the safety and efficacy of amprenavir [APV/j Agenerase trade mark; GlaxoSmithKline, [Ware, UK; 600 mg twice a day (bid)] boosted with low-dose ritonavir (RTV, 100 mg bid) with those of other protease inhibitors (PIs) in PI-experienced HIV-infected patients. STUDY DESIGN:Parallel-group, randomized...

journal_title：HIV medicine

authors： Pulido F,Katlama C,Marquez M,Thomas R,Clumeck N,Pedro Rde J,Cattelan AM,Zhu C,Tymkewycz P

更新日期：2004-07-01 00:00:00

abstract：OBJECTIVES:Financial stress has been identified as a barrier to antiretroviral adherence, but only in resource- limited settings. Almost half of HIV-infected Australian adults earn no regular income and, despite highly subsidised antiretroviral therapy and universal health care, 3% of HIV-infected Australians cease ant...

journal_title：HIV medicine

authors： McAllister J,Beardsworth G,Lavie E,MacRae K,Carr A

更新日期：2013-02-01 00:00:00

abstract：OBJECTIVES:Certain non-AIDS-related diseases have been associated with immunodeficiency and HIV RNA levels in HIV-infected patients on combination antiretroviral therapy (cART). We aimed to investigate these associations in patients not yet on cART, when potential antiretroviral-drug-related effects are absent and vari...

journal_title：HIV medicine

authors： Zhang S,van Sighem A,Kesselring A,Gras L,Prins JM,Hassink E,Kauffmann R,Richter C,de Wolf F,Reiss P,ATHENA national observational HIV cohort study.

更新日期：2015-05-01 00:00:00

abstract：OBJECTIVES:To assess the efficacy and safety of adefovir dipivoxil (ADV) added to stable background antiretroviral therapy (ART) in HIV-infected individuals with advanced HIV disease. METHODS:ADHOC was a randomized, double-blind, placebo-controlled, international multicentre trial. Three hundred and one individuals wi...

journal_title：HIV medicine

authors： ADHOC International Steering Committee.

更新日期：2002-10-01 00:00:00

abstract：OBJECTIVES:Effective HIV therapy reflects suppression of plasma HIV RNA levels below assay detection thresholds, although lower levels of "residual viraemia" have also been demonstrated over extended periods of effective antiretroviral treatment. Here we examine the determinants of HIV RNA suppression below the standar...

journal_title：HIV medicine

authors： McKinnon E,Castley A,Payne L,Pummer S,Nolan D

更新日期：2016-08-01 00:00:00

abstract：OBJECTIVES:Renal disease is a common and serious complication in HIV-infected patients. METHODS:A retrospective cohort analysis for the period 1989-2010 was carried out to determine the prevalence, incidence and risk factors for end-stage renal disease (ESRD). ESRD was defined as initiation of renal replacement therap...

journal_title：HIV medicine

authors： Bickel M,Marben W,Betz C,Khaykin P,Stephan C,Gute P,Haberl A,Knecht G,Wolf T,Brodt HR,Geiger H,Herrmann E,Jung O

更新日期：2013-03-01 00:00:00

abstract：OBJECTIVES:Across Europe, almost a third of individuals infected with HIV do not enter health care until late in the course of their infection. Surveillance to identify the extent to which late presentation occurs remains inadequate across Europe and is further complicated by the lack of a common clinical definition of...

journal_title：HIV medicine

authors： Antinori A,Coenen T,Costagiola D,Dedes N,Ellefson M,Gatell J,Girardi E,Johnson M,Kirk O,Lundgren J,Mocroft A,D'Arminio Monforte A,Phillips A,Raben D,Rockstroh JK,Sabin C,Sönnerborg A,De Wolf F,European Late Presenter

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVES:The aims of the present study were to estimate the prevalence of renal impairment (RI) among HIV-infected adult patients and to investigate the associated factors. METHODS:A cross-sectional survey was conducted in a French hospital-based cohort. Clearance of creatinine (CC) was calculated using the Cockcrof...

journal_title：HIV medicine

authors： Déti EK,Thiébaut R,Bonnet F,Lawson-Ayayi S,Dupon M,Neau D,Pellegrin JL,Malvy D,Tchamgoué S,Dabis F,Morlat P,Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

更新日期：2010-05-01 00:00:00

abstract：OBJECTIVES:HIV-associated neurocognitive disorders are highly prevalent, and physical activity (PA) is a modifiable behaviour that may affect neurocognitive function. Our objective was to determine the association between PA and neurocognitive function and the effect of HIV on this association. METHODS:PA was assessed...

journal_title：HIV medicine

authors： Monroe AK,Zhang L,Jacobson LP,Plankey MW,Brown TT,Miller EN,Martin E,Becker JT,Levine AJ,Ragin A,Sacktor NC

更新日期：2017-09-01 00:00:00

abstract：OBJECTIVES:Antiretroviral therapy (ART) has been associated with unfavourable lipid profile changes and increased risk of cardiovascular disease (CVD). With a growing population on ART in South Africa, there has been concern about the increase in noncommunicable diseases such as CVD. We determined risk factors associat...

journal_title：HIV medicine

authors： Jamieson L,Evans D,Brennan AT,Moyo F,Spencer D,Mahomed K,Maskew M,Long L,Rosen S,Fox MP

更新日期：2017-09-01 00:00:00

abstract：OBJECTIVES:Despite the benefits of HAART, initiation of antiretroviral therapy in HIV-HCV co-infected patients is often delayed as a consequence of patient and physician concern pertaining to liver toxicity. It is unclear whether this is justified. METHODS:We retrospectively evaluated treatment duration and outcome in...

journal_title：HIV medicine

authors： Cooper CL,Breau C,Laroche A,Lee C,Garber G

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVES:The incidence of sexually transmitted infections (STIs) and HIV infection remains high in gay, bisexual, and other men who have sex with men (MSM) in the UK, and sexualized drug use ("chemsex") and injecting drug use ("slamsex") may play a part in this. We aimed to characterize HIV-positive MSM engaging in c...

journal_title：HIV medicine

authors： Pufall EL,Kall M,Shahmanesh M,Nardone A,Gilson R,Delpech V,Ward H,Positive Voices study group.

更新日期：2018-04-01 00:00:00

abstract：OBJECTIVES:The World Health Organization (WHO) recommends screening HIV-infected people for cryptococcal antigens to identify cryptococcosis, a major cause of AIDS-related deaths. As the burden of cryptococcosis is unknown in South Africa's KwaZulu-Natal province, we assessed the cryptococcal antigenuria prevalence amo...

journal_title：HIV medicine

authors： Drain PK,Kleene JM,Coleman SM,Losina E,Katz JN,Giddy J,Ross D,Freedberg KA,Bassett IV

更新日期：2015-11-01 00:00:00

abstract：OBJECTIVES:Three-drug nonoccupational post-exposure prophylaxis (NPEP) typically includes co-formulated emtricitabine-tenofovir (FTC-TDF) and a protease inhibitor. However, protease inhibitors can cause significant toxicities, can interact with prescribed and illicit drugs, and work late in the viral cycle. Agents that...

journal_title：HIV medicine

authors： McAllister J,Read P,McNulty A,Tong WW,Ingersoll A,Carr A

更新日期：2014-01-01 00:00:00

abstract：OBJECTIVES:For the last 10 years there has been an epidemic of hepatitis C virus (HCV) infection in men who have sex with men (MSM) in Europe, North America and Australia. The majority of those infected are also HIV-positive and it is unclear to what extent HIV-negative MSM are also at increased risk of infection with ...

journal_title：HIV medicine

authors： Price H,Gilson R,Mercey D,Copas A,Parry J,Nardone A,Johnson A,Hart G

更新日期：2013-10-01 00:00:00

abstract：INTRODUCTION:Hyperlipidaemia is a recognized complication of HIV antiretroviral therapy. The interactions among HIV, viral hepatitis, antiretroviral therapies and lipids are poorly understood. METHODS:Ontario HIV Treatment Network Cohort Study participants with at least one lipid level after highly active antiretrovir...

journal_title：HIV medicine

authors： Diong C,Raboud J,Li M,Cooper C,Ontario HIV Treatment Network Cohort Study Team.

更新日期：2011-08-01 00:00:00

abstract：OBJECTIVES:The aim of the study was to assess indicator condition (IC) guided HIV testing in Estonia from 2012-2015. METHODS:We used Estonian Health Insurance Fund (EHIF) data. EHIF is the core purchaser of health care services in Estonia, covering health care costs for insured people (94% of the total population). Af...

journal_title：HIV medicine

authors： Rüütel K,Lemsalu L,Lätt S,OptTEST by HiE.

更新日期：2018-02-01 00:00:00

abstract：OBJECTIVES:As more HIV-positive individuals receive antiretroviral therapy (ART), payers are seeking options for covering these increased and sustained drug costs. Strategic use of available generic antiretroviral (ARV) formulations may be feasible. De-simplifying a single-tablet co-formulation (STF) into two or more t...

journal_title：HIV medicine

authors： Krentz HB,Campbell S,Lahl M,Gill MJ

更新日期：2019-03-01 00:00:00